Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135363 | 1.00 | UBE2M (0.39) | UBE2MDCUN1D1HPGDALDH1A1MEN1 | |
| SCHEMBL20135224 | 0.88 | ADAMTS5 (0.38) | UBE2MDCUN1D1HPGDALDH1A1MEN1 | |
| SCHEMBL20135225 | 0.88 | ADAMTS5 (0.38) | UBE2MDCUN1D1HPGDALDH1A1MEN1 | |
| SCHEMBL20134970 | 0.84 | MGLL (0.39) | UBE2MDCUN1D1HPGDALDH1A1MEN1 | |
| SCHEMBL20134774 | 0.84 | UBE2M (0.39) | UBE2MDCUN1D1MEN1KMT2AMAPK7 | |
| SCHEMBL20134973 | 0.84 | MGLL (0.39) | UBE2MDCUN1D1HPGDALDH1A1MEN1 | |
| SCHEMBL20134773 | 0.84 | UBE2M (0.39) | UBE2MDCUN1D1MEN1KMT2AMAPK7 | |
| SCHEMBL20134794 | 0.82 | MEN1 (0.39) | UBE2MDCUN1D1HPGDALDH1A1MEN1 | |
| SCHEMBL20134792 | 0.82 | MEN1 (0.39) | UBE2MDCUN1D1HPGDALDH1A1MEN1 | |
| SCHEMBL20791691 | 0.79 | UBE2M (0.40) | UBE2MDCUN1D1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | UBE2M 2697/4885DCUN1D1 3076/4885HPGD 74/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | UBE2M 2592/4885DCUN1D1 3027/4885HPGD 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.